RESUMEN
PURPOSE: This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study. PATIENTS AND METHODS: Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires before cycle 1, at weeks 7 and 13, and at the end of treatment. In total, 1437 patients (mean age, 59.6 years [+/- 13.5 years]) were enrolled. RESULTS: In women, statistically significant improvements were observed in 6 QLQ-C30 and 6 QLQ-CR38 domains (QLQ-C30: emotional function, nausea/ vomiting, pain, constipation, financial problems, and body image; QLQ-CR38: future perspective, micturition problems, defecation problems, stoma-related problems, weight loss and global health status). In men, statistically significant improvements were observed in 8 QLQ-C30 and 5 QLQ-CR38 domains (QLQ-C30: emotional function, social function, pain, insomnia, appetite loss, constipation, financial problems, and future perspective; QLQ-CR38: micturition problems, defecation problems, stoma-related problems, weight loss, and global health status). Statistically significant worsening of sexual function/enjoyment occurred in both sexes. CONCLUSION: Overall, 59%-86% of patients maintained or improved QOL during capecitabine therapy.